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Phenotypic screening of a 900 compound library of antitubercular nitroimidazole derivatives 
related to pretomanid against the protozoan parasite Trypanosoma cruzi (the causative agent 
for Chagas disease) identified several structurally diverse hits with an unknown mode of action. 
Following initial profiling, a first proof-of-concept in vivo study was undertaken, in which once 
daily oral dosing of a 7-substituted 2-nitroimidazooxazine analogue suppressed blood 
parasitemia to low or undetectable levels, although sterile cure was not achieved. Limited hit 
expansion studies alongside counter-screening of new compounds targeted at visceral 
leishmaniasis laid the foundation for a more in-depth assessment of the best leads, focusing on 
both drug-like attributes (solubility, metabolic stability and safety) and maximal killing of the 
parasite in a shorter timeframe. Comparative appraisal of one preferred lead (58) in a chronic 
infection mouse model, monitored by highly sensitive bioluminescence imaging, provided the 









CD, Chagas disease; T. cruzi, Trypanosoma cruzi; HAT, human African trypanosomiasis; IPK, 
Institut Pasteur Korea; HLM, human liver microsomes; PK, pharmacokinetic; p.i., post-
infection; MLM, mouse liver microsomes; STI, Swiss Tropical Institute; DIPEA, N,N-
diisopropylethylamine; MEK, methyl ethyl ketone (2-butanone); NTR, nitroreductase; 





Chagas disease (CD) or American trypanosomiasis is a neglected tropical disease that afflicts 
approximately 7 million people worldwide and claims at least 10,000 lives every year [1]. Once 
endemic almost exclusively to poor or rural areas of Latin America, CD has now spread into 
many high-income countries in Europe, North America, and the Western Pacific [2,3]. The 
causative parasite, Trypanosoma cruzi (T. cruzi), is transmitted primarily via the faeces of a 
blood-sucking triatomine insect known as the ‘kissing bug’, which commonly infests 
substandard housing; many animals also function as disease reservoirs [1-3]. Following 
infection, a one- to two-month acute illness develops, which is usually mild or asymptomatic, 
although it can be fatal in 5% of diagnosed cases due to the high parasitic burden. The host 
immune system then takes over, rendering even parasite detection extremely difficult [2,4]. 
Eventually, sometimes decades later, a chronic disease state can manifest in digestive or cardiac 
disorders, which may lead to malnutrition, progressive heart failure and sudden death [1,3]. 
However, in 2015, it was estimated that more than 80% of individuals affected by CD globally 
did not have access to diagnosis and specific treatment [5]. 
There is currently no vaccine for CD and just two drugs are available for therapy, benznidazole 
(1) and nifurtimox (2) (Fig. 1), both of which can induce serious adverse effects during dosing 
periods of 60-90 days [2,6,7]. Recent clinical trial failures with two azole drugs, posaconazole 
(3) and E1224 (5, a prodrug of ravuconazole 4), have emptied the late-stage candidate pipeline, 
providing fresh impetus for the development of new assessment tools with superior predictivity 
[4,8-12]. One encouraging result is that the repositioned antimicrobial agent fexinidazole (6), 
a safe and effective newly approved drug for late-stage human African trypanosomiasis (HAT) 
[13], has shown curative activity potentially better than 1 in acute stage CD mouse models and 
equivalent to 1 in the chronic stage models, as revealed by highly sensitive bioluminescence 
imaging [14]. Although a phase II proof of concept clinical study of 6 was interrupted because 
of safety and tolerability issues at higher doses and longer treatment times, good efficacy 
against CD was observed at more tolerable doses; therefore, a second clinical trial has been 
initiated [15,16]. A close analogue of the HAT clinical candidate SCYX-7158 (7), oxaborole 
SCYX-6759 (8), also exhibited strong in vivo activity against CD but was not curative in the 
chronic model [17]. Amongst many novel lead molecules evaluated in mice [18-21], the most 
promising was proteasome inhibitor GNF6702 (9), which delivered an 88% cure rate for 
treating chronic infection when dosed twice daily for 20 days [22]. Nevertheless, a five day 
schedule using higher doses of 9 did not achieve any cures in the acute model [23], and a new 
article by Rao et al. [24] that compares 9 with a more recent analogue (for HAT) still provides 
no indication whether this pan-kinetoplastid drug candidate has progressed beyond preclinical 
toxicology. Hence, there remains a compelling need to discover new medicines for CD. 
In CD research, successful target-based drug discovery has been hindered by the lack of well-
validated targets [25]. Hence, phenotypic screening of various compound collections, seeking 
to exploit existing chemical matter, is still considered to be the most useful and cost-effective 
strategy to identify new leads or starting points [25,26]. Pretomanid (PA-824, 10) is an orally 
active drug that was recently approved by the FDA to treat highly challenging cases of 
tuberculosis [27]. We have previously recounted that phenotypic screening (instigated by the 
Drugs for Neglected Diseases initiative, DNDi [28]) of bicyclic nitroimidazole derivatives 
generated in our quest for an improved backup to 10 (with the TB Alliance [29]) led to the 
novel discovery of their potent antileishmanial activity [30,31]. Collaborative lead optimisation 
efforts with DNDi in the very promising 7-substituted 2-nitroimidazooxazine class eventually 
culminated in the development of clinical candidate DNDI-0690 (11) [31], having comparable 
efficacy but greater safety than the original preclinical nominee, DNDI-VL-2098 (12) [30]. As 
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part of the early investigations (2010), a 900-member subset of the pretomanid analogue library 
above was counter-screened against intracellular Y strain T. cruzi amastigotes, using an image-
based assay [8] (with 7 data points and 3-fold dilutions) run at the Institut Pasteur Korea (IPK). 
Following initial profiling of the best screening hits, we conducted some limited hit expansion 
work alongside our primary studies directed at leishmaniasis. Testing of these new compounds 
against T. cruzi pinpointed several that displayed submicromolar activity, some of which have 
been further assessed (e.g., for solubility, microsomal stability, T. cruzi CYP51 inhibition and 
maximal parasite killing in a 48 hour exposure assay). We now report the findings from our 














































































Fig. 1. Various antitrypanosomal, antitubercular, or antileishmanial agents. 
2. Results and discussion 
2.1 Initial examination of library screening hits 
The structures and in vitro biological assay data for selected IPK screening hits (based mainly 
on % inhibition data) are summarised in Table 1. The IC50 and IC90 data against intracellular 
T. cruzi (transfected Tulahuen strain TcVI) or L6 host cells (rat skeletal myoblasts) were 
derived from replicate assays performed at Murdoch University [32], using fresh sample stock. 
Most of the hits provided submicromolar IC50 and IC90 values and displayed very low 
cytotoxicity, resulting in excellent selectivity indices (typically >200), but biphenyl analogues 
16 and 21 [33] were much less effective. Unsurprisingly, these lipophilic compounds 
demonstrated very low aqueous solubilities. Five examples (13-17) [31,33-35] were also tested 
for stability in the presence of human liver microsomes (HLM). The first three showed more 
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rapid metabolism, consistent with known pharmacokinetic (PK) issues associated with the less 
stable 4-benzyloxybenzyl ether side chain (previously substantiated in both the 
nitroimidazooxazine and nitroimidazothiazine classes) [36,37]. This trend was further 
reinforced by measuring plasma concentrations of 13-17 in mice at time intervals of 0.5, 8 and 
24 hours, following oral administration at 50 mg/kg. Only compounds 16 and 17 [31] gave 
plasma concentrations that were greater than their in vitro IC50 values at all time points (mean 
results at 24 hours were 9.1 and 0.78 µM, respectively; see the Supplementary data). These hits 
also showed little propensity to inhibit CYP3A4 (IC50 values >20 µM). 






































































Compd IPK Screena IC50 (µM)b IC90 (µM)b Selectivity Solubilityd Stabilitye 
 (% at x µg/mL) T. cruzi L6 T. cruzi Indexc (µg/mL) t1/2 (min) 
13 89% at 10 0.035 >100 0.089 >2857 0.44 156 
14 95% at 10 0.28 >100 0.44 >357 0.13 103 
15 59% at 3.3 0.083 >100 0.24 >1205 <0.1 25 
16 94% at 10 3.7 34 8.0 9.2 0.48 >250 
17 52% at 3.3 0.45 >100 0.93 >222 2.3 >250 
18 50% at 3.3 0.31 >100 0.90 >323 0.69 (13) ND 
19 48% at 1.1 0.23 >100 0.59 >435 0.33 (6.8) ND 
20 44% at 0.37 0.32 >100 0.99 >313 0.49 (4.4) >250 
21 65% at 10 >10 13 >10 ND ND ND 
22 58% at 1.1 1.6 >100 6.3 >63 8750 ND 
23 (12% at 10)f 0.047 >100 0.13 >2128 0.18 ND 
24 29% at 1.1 0.022 >100 0.19 >4545 1.1 (19) ND 
aPercentage inhibition of the growth of T. cruzi at the primary screen concentration (in µg/mL). 
bIC50 or IC90 values for inhibition of the growth of T. cruzi or for cytotoxicity toward L6 cells. 
Each value is the mean of ≥2 independent determinations. cRatio of L6 to T. cruzi IC50 values. 
dKinetic solubility in water, pH 7 (data in parentheses for 0.1 M HCl, pH 1; ND means not 
determined). eHalf-life in human liver microsomes (data from a 60 min incubation). fLate 
inclusion based on promising data in an earlier T. cruzi assay run at the Swiss Tropical Institute. 
2.2 Evaluation of hit 17 in an acute infection mouse model of CD  
With these results in hand, a proof-of-concept in vivo efficacy study of 17 was initiated, using 
posaconazole (3) as a positive control. Briefly, female Swiss mice (5 per group) were infected 
intraperitoneally with 5 x 104 bloodstream form trypomastigotes of T. cruzi (Tulahuen strain). 
Oral dosing of compounds commenced on day 8 post-infection (p.i.), and continued once daily 
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for 20 days. Blood parasitemia was monitored during this period and mice having very low or 
undetectable parasite levels after the end of dosing and 10 days of rest were immunosuppressed 
via three rounds of treatment with cyclophosphamide (50 mg/kg once daily for 4 days, then 3 
days of rest) to release any parasites that were being harboured in tissues [32]. In the absence 
of any therapy (vehicle only), all mice presented high parasitemia by day 12 p.i. In contrast, by 
day 28 p.i., treatment with 3 (20 mg/kg) had reduced parasite load below the detection limit in 
all five mice (Fig. 2a). However, after two rounds of immunosuppression (day 51 p.i.), parasite 
numbers had rebounded in three of the mice, and parasites were detected in the remaining two 
mice by PCR. Treatment with compound 17 (50 mg/kg) similarly decreased parasite load 
completely in 60% of mice, and greatly reduced parasitemia in the remainder (Fig. 2b), leading 
to 100% survival. Nevertheless, two rounds of immunosuppression subsequently led to the 
restoration of high parasite levels in all mice. Hence, while 17 showed promising efficacy in 
the acute phase of this study, like 3 (and oxaborole 8, as reported earlier [17]), it did not 
ultimately deliver any complete cures. But success in treating this stringent model may require 
24 hour plasma levels above the IC50 to be much higher than what was attained with 17 [32], 
implying the need for compounds with a superior PK profile and/or greater potency. 
 
Fig. 2. Parasitemia levels in individual T. cruzi-infected mice over 20 days of oral treatment 
with a) 3 (20 mg/kg) or b) 17 (50 mg/kg) and then three 7-day cycles of immunosuppression. 
2.3 Design and synthesis of new analogues 
Looking at the remaining hits in Table 1, 18 [31] was not considered for in vivo study because 
it was rapidly metabolised by mouse liver microsomes (MLM; only 33% remained after a 30 
min incubation [31]) and we held similar concerns about 23 [34] and 24 [38]. Therefore, at this 
point, we elected to perform some limited hit expansion work around 16, 17, 19 and 20 [36] to 
see if we could further improve potency and/or metabolic stability. In the mouse PK work 
above, the plasma concentration of 16 at 24 hours was 9.1 µM, 12-fold higher than that of 17, 
but the potency of 16 was insufficient. Nevertheless, previous screening of an unsubstituted 
biphenyl analogue of 16 (25) [33] and its 6R enantiomer (ent-25) against intracellular T. cruzi 
(Tulahuen C2C4 strain) at the Swiss Tropical Institute (STI) had indicated that the latter was 
strongly preferred (22-fold; Fig. 3), suggesting that the enantiomers of 16, 19 and 20 should be 
investigated. With 17, we considered four alternative strategies for structural modification: (i) 
addition of a halogen atom to the 4-trifluoromethoxyphenyl ring (to block a potential site for 
metabolism); (ii) replacement of the ring oxygen by sulphur (and its oxide forms); (iii) 
replacement of the nitroimidazole ring by nitrotriazole; (iv) use of heterobiaryl side chains in 
the typically more potent 7H series. Proposals (ii) and (iii) were based on a comparison of 13 
and 23 with 2-nitroimidazooxazine/thiazine counterparts 26 and 27 [34] (Fig. 3), whereas 
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Fig. 3. Additional key data employed in the design of new targets. 
The synthetic routes that were used to prepare these 13 new compounds are outlined below. 
The enantiomers of 16 and its 4-trifluoromethoxy congener 30 [33] were generated by Suzuki 
coupling reactions on the 4-bromobenzyl ether derivative of known 6R alcohol 28 [39], i.e. 29 
(Scheme 1A). In similar fashion, phenylpyridine analogues 33 and ent-33 were sourced from 
the 6S bromopyridine precursor 32 [40], or from 6R alcohol 28 and bromide 31 [40] (via ent-
32), respectively. The construction of ent-19 and ent-20 involved successive Sonogashira and 
Suzuki reactions on key propargyl ether intermediate 36, which was itself formed by alkylation 

























































































Scheme 1. Synthesis of new 6R enantiomers in the pretomanid class. 
Reagents and conditions: (i) NaH, DMF, 0-20 °C, 1.8-3 h (87-95%); (ii) ArB(OH)2, DMF, 
(toluene, EtOH), 2 M Na2CO3 or 2 M KHCO3, Pd(dppf)Cl2 under N2, 70-89 °C, 1-16 h (34-
81%); (iii) TBAF, THF, 0-6 °C, 2.5 h (81%); (iv) 5-bromo-2-iodopyridine, DIPEA, THF, 
DMF, CuI, Pd(PPh3)2Cl2 under N2, 20 °C, 24 h (82%). 
Halide derivatives of 17 (42-44) were obtained from epoxide 38 (Scheme 2A) through ring 
opening with the required phenols (K2CO3, MEK, 80 °C), followed by sodium hydride-assisted 
ring closure of alcohol intermediates 39-41, as reported for 17 [31]. Serendipitously, we 
discovered that treatment of 38 with thiourea on silica gel [42] readily afforded thiirane 45 
(Scheme 2B) and that ring-opening of 45 with excess 4-(trifluoromethoxy)phenol (10 equiv) 
gave the desired 2-nitroimidazothiazine 46 directly, as the major product (27%). The low yield 
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in this latter case reflected the coproduction of polar decomposition material, possibly due to 
some competing reduction of the nitro group by the intermediate thiolate (at 80 °C). Buffered 
oxidations of 46 with m-CPBA (1.1 or 3.0 equiv) then selectively formed the monoxide (47) 
and dioxide (48) derivatives in high yield (88-96%). However, we postulated that the higher 
reactivity of 5-halo-3-nitrotriazoles toward nucleophiles would likely preclude the successful 
synthesis of triazole 56 using a similar epoxide-opening strategy. To circumvent this issue, the 
non-triazole portion of 56 was first assembled as iodide 53 (Scheme 2C), starting from the 
known epoxide 49 [43] [via successive epoxide ring opening with 4-(trifluoromethoxy)phenol, 
TBS-protection of the resulting tertiary hydroxyl group in 50, hydrogenolysis to cleave the 
benzyl ether, and iodination of the obtained alcohol 52]. Subsequently, iodide 53 was reacted 
with 5-bromo-3-nitro-1H-1,2,4-triazole (54) to produce the crude silyl ether 55. Desilylation 
of the latter with TBAF then effected concomitant cyclization, giving the required 
nitrotriazolooxazine 56 in modest yield (28%). Competing hydrolysis of the activated bromide, 





























































































42: R=2-Cl; 43: R=3-Cl; 44: R=3-F
 
Scheme 2. Synthesis of new analogues in the 7-substituted oxazine/thiazine classes.  
Reagents and conditions: (i) ArOH, K2CO3, MEK, 80-83 °C, 10.5-108 h (39-41: 68-72%; 46: 
27%; 50: 81%); (ii) NaH, DMF, 20 °C, 2.5-3 h (57-77%); (iii) thiourea on silica gel, CH2Cl2, 
20 °C, 6.5 h (79%); (iv) m-CPBA, Na2HPO4, CH2Cl2, 20 °C, 17-53 h (88-96%); (v) TBSOTf, 
2,6-lutidine, CH2Cl2, 0-20 °C, 66 h (95%); (vi) H2, Pd/C, EtOH, EtOAc, 20 °C, 42 h (100%); 
(vii) I2, PPh3, imidazole, CH2Cl2, 20 °C, 39 h (96%); (viii) K2CO3, DMF, 73 °C, 61 h (45%); 
(ix) TBAF, THF, 0-20 °C, 24 h (28%). 
2.4 Initial in vitro assessment of new and known analogues 
The biological effects of our initial hit expansion work around 16 are recorded in Table 2. 
While close analogues 30 and 33 did not show better activity than 16, the 6R enantiomers of 
all three compounds (ent-16, ent-30, and ent-33) were an order of magnitude more growth 
inhibitory against T. cruzi, having potencies comparable to that of the known [44] 6R 
enantiomer of pretomanid (ent-10). Both 6S and 6R forms were similarly cytotoxic toward L6 
host cells, so this increased activity for the latter derivatives translated into greatly improved 
selectivity indices (values >100, compared to only 3-12 for 16, 30, and 33). Continued 
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optimisation of the phenylpyridine class exemplified by ent-33 as antileishmanial agents 
(counter-screening against T. cruzi) led to compounds with very high potencies (e.g., 57: IC50 
0.049 µM), but these were metabolised much more rapidly (half-lives of ~30 min in HLM; 
Table 3) and were found to be strong inhibitors of the hERG channel (e.g., 57: IC50 0.81 µM 
cf. >30 µM for 16) [45]. Amongst monoaryl counterparts, ent-10 displayed good solubility but 
was reportedly cleared faster than 10 in vivo, such that plasma levels were undetectable by 24 
hours [44]. However, close analogue 58 was identified as a potential lead for CD, given its 
good in vitro activity (IC90 1.0 µM), acceptable aqueous solubility (12 µg/mL), and excellent 
rodent PK and safety profile [45]. 





























Compd IC50 (µM)a IC90 (µM)a Selectivity 
 T. cruzi L6 T. cruzi Indexb 
16 3.7 34 8.0 9.2 
30 5.7 19 >10 3.3 
33 4.8 57 >10 12 
ent-10 0.30 72 1.4 240 
ent-16 0.25 29 0.71 116 
ent-30 0.24 25 1.1 104 
ent-33 0.67 50 2.9 75 
57 0.049 51 0.31 1041 
58 0.40 >100 1.0 >250 
aIC50 or IC90 values for inhibition of the growth of T. cruzi or for cytotoxicity toward L6 host 
cells. Each value is the mean of ≥2 independent determinations. bRatio of L6 to T. cruzi IC50 
values. 
In the 7-substituted 2-nitroimidazooxazine class (Table 4), addition of a chlorine or fluorine 
atom to the 4-trifluoromethoxyphenyl ring of 17 (42-44) seemed to be fairly well tolerated, but 
this modification unexpectedly led to more rapid rates of metabolism by HLM and MLM 
(Table 3). Furthermore, exchange of the oxazine ring of 17 for thiazine and its oxides (46-48) 
did not furnish the same enhancement in potency observed in the parent 6-substituted series 
(cf. 13 and 14 vs 26). Therefore, we switched our attention to heterobiaryl side chains in the 
more active 7H series [31] (Table 5). Here, the incorporation of 2,6-pyrimidine or 2-pyridine 
as the first ring (61 and 63) [31] was particularly efficacious (IC90s 0.18-0.33 µM) but the 
compounds were only sparingly soluble (Table 3). More extensive optimisation of this biaryl 
class for visceral leishmaniasis led to the identification of rac-11 as a lead with good T. cruzi 
activity (similar to its 4-trifluoromethoxy counterpart 64), but the standout new hit for CD was 
65 [31]. This compound had superb potency (IC90 0.044 µM) and low cytotoxicity (IC50 >100 
µM), giving a very high selectivity index (>5556); it also demonstrated solubility comparable 
to rac-11 (at pH 7) and excellent MLM stability (90% parent after 1 h; Table 3).  
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Table 3. Aqueous solubility, microsomal stability, and hERG data for selected compounds. 
Compd Aq. Solubilitya 
(µg/mL) 
Microsomesb (% 
remaining at 1 h) 
hERG 
IC50 
 pH 7 pH 1 Human Mouse (µM) 
ent-10c 18  92 86  
rac-11d 0.32 164 44 34 >30 
rac-12e 3.6    5.6 
16f 0.48  92 93 >30 
ent-16 <0.1  76 83  
17d 2.3  58 50 3.8 
19g 0.33 6.8    
ent-19 0.68 7.6 58 76  
20g 0.49 4.4 89 86  
ent-20 <0.1 3.0 68 74  
ent-30 <0.1  85 76  
ent-33 1.0 299    
42 0.61  6.4 9.1  
43 0.50  11 8.8  
44 0.95  26 23  
48 1.1  88 76  
56 9.5h  91 92  
57c 3.0 1040 27 36 0.81 
58c 12  81 79 >30 
59d <0.1     
60d 0.46     
61d <0.1     
62d <0.1     
63d <0.1 0.9    
64d 0.15 138 53 41  
65d 0.36  72 90  
70c 0.85  80 76  
aKinetic solubility in water (pH 7) or 0.1 M HCl (pH 1), determined by HPLC. bPooled human 
or CD-1 mouse liver microsomes. cRef. 45. dRef. 31. eRef. 30. fRef. 33. gRef. 36. h1% DMSO. 
















Compd R or X IC50 (µM)a IC90 (µM)a Selectivity 
  T. cruzi L6  Indexb 
17  0.45 >100 0.93 >222 
42 2-Cl 0.46 >100 1.3 >217 
43 3-Cl 0.31 53 6.5 171 
44 3-F 0.56 68 1.9 121 
46 S 1.1 >100 2.6 >91 
47 SO 1.6 73 3.7 46 
48 SO2 0.70 >100 1.6 >143 
a,bAs for Table 2. 
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Compd Aza IC50 (µM)a IC90 (µM)a Selectivity 
  T. cruzi L6 T. cruzi Indexb 
59 2′,3′ 0.38 42 0.96 111 
60 2′,5′ 0.21 >100 6.7 >476 
61 2′,6′ 0.053 19 0.33 358 
62 3′,5′ 0.33 70 0.96 212 
63 2′ 0.040 >100 0.18 >2500 
64 3′ 0.24 >100 0.99 >417 
rac-11  0.17 >100 0.56 >588 
65  0.018 >100 0.044 >5556 
a,bAs for Table 2. 
2.5 Further in vitro assessment of various new and known leads 
Selected compounds from this work and our previous studies [30,31,45] (Table 6) were then 
further profiled in vitro at the University of Dundee and Griffith University to respectively test 
for inhibition of sterol 14α-demethylase (CYP51) in T. cruzi (the commonly targeted 
mechanism of action of azoles 3-5 that we wished to avoid, due to the failure of such drugs in 
CD clinical trials) [46] and for the ability to achieve 100% trypanocidal activity against T. cruzi 
(Tulahuen strain) amastigotes in a shorter 48 (vs 96) hour assay [47] (a distinguishing feature 
of 1 and 2 over 3 and other CD drug candidates [8]). In the initially studied (for leishmaniasis) 
imidazooxazole class [30], both the des-nitro analogue 66 and 5-bromo derivative 67 showed 
submicromolar inhibition of CYP51 (IC50s 0.16 and 0.53 µM, respectively), possibly 
accounting (at least in part) for their unexpected activities against T. cruzi. However, some 
conversion of the photosensitive 67 to 66 prior to or during this assay could not be excluded 
because 5-thioether 68 displayed no inhibition of CYP51. Importantly, nitro derivatives across 
all compound classes were generally inactive against CYP51 (IC50s >10 µM), implying a 
mechanism of action different to that of azoles 3-5. 
Continued examination of oxazole-based classes revealed that for the two more potent nitro 
compounds (rac-12 and 69: IC90s 2.3 and 2.1 µM, respectively) there were substantial 
differences in their maximal inhibitory activities against T. cruzi in this shorter (48 h) assay, 
with triazole 69 (96%) being much more effective than its imidazole counterpart rac-12 (68%). 
Intriguingly, the tuberculosis drug delamanid (a 2-nitroimidazooxazole) was similarly reported 
to be a slow cidal inhibitor of T. cruzi in vitro (a characteristic also shown by CYP51 inhibitors 
[8]), and this was postulated to be a predictive factor for its failure to demonstrate in vivo 
efficacy in a CD mouse model [48]. The mechanism of action of delamanid for CD has not 
been determined but a novel nitroreductase (NTR2) in Leishmania (rather than the previously 
identified type I nitroreductase NTR1) was shown to be responsible for mediating its 
antileishmanial effects [49]. The involvement of an analogous new target in CD would be 
consistent with evidence from studies in HAT revealing a lack of cross resistance between 
pretomanid (10) and nifurtimox (2) [50], and that a more potent 6-amino-linked analogue of 
10 was not activated by NTR1 [51]. Nonetheless, a nitroreductase-based mechanism would not 
explain the inhibitory activity of 5-thiomethyl derivative 68. 
12 
 








































Compd IC50 (µM)a IC90 (µM)a Selectivity Maximum Hill 
 T. cruzi 3T3 CYP51 T. cruzi Indexb Activity (%) Slope 
1 12 >127 >10c 37 >11 101 2.4 
2 2.1 >127 >10c 4.6 >60 99 2.7 
3 0.0012 >1 0.052 0.0049 >833 85 1.8 
Pretomanid class 
ent-10 0.89 >37 >10 5.9 >42 94 1.2 
ent-16 0.28 >37 7.6 0.41 >132 100 6.3 
19 0.51 >37 >10 1.7 >73 97 1.9 
ent-19 0.27 >37 >10 1.7 >137 95 1.2 
20 0.73 >37 >10 1.0 >51 99 7.0 
ent-20 0.67 >37 >10 2.2 >55 94 1.8 
ent-30 0.57 >37 >10 1.0 >65 99 4.6 
57 0.39 >73 >10 2.6 >187 80 1.2 
58 1.2 >73 >10 1.7 >61 99 12 
70 0.19 >37 >10 0.44 >195 99 2.8 
7-Substituted oxazine/thiazine classes 
17 0.17 >37 >10 1.0 >218 100 1.3 
48 1.3 >37 >10 3.0 >28 101 2.6 
56 0.22 >37 >10 0.85 >168 96 1.7 
64 1.0 >73 >10 1.5 >73 100 5.6 
65 0.074 >37 >10 0.33 >500 98 1.5 
Imidazooxazole/Triazolooxazole classes 
rac-12 0.95 >73 >10 2.3 >77 68 3.4 
66 4.7 >73 0.16 10 >16 80 2.9 
67 1.7 >73 0.53 4.1 >43 87 6.8 
68 2.0 >73 >10 16 >37 93 1.1 
69 0.72 >73 >10 2.1 >101 96 2.0 
aIC50 or IC90 values for inhibition of the growth of T. cruzi (48 hour assay), for cytotoxicity 
toward 3T3 cells, or for inhibition of T. cruzi CYP51. Each value (except the single test CYP51 
data) is the mean of 2 independent determinations (for standard deviations, see the 
Supplementary data). bRatio of 3T3 to T. cruzi IC50 values. cData from ref 11. 
In the pretomanid class, several compounds (ent-16, 20, ent-30, 58 and 70) showed maximal 
inhibitory activities of 99-100%, of which ent-16 and arylpropargyl ether 70 were the most 
potent (IC90s 0.41 and 0.44 µM, respectively). However, ent-10, 19, and the 6R enantiomers of 
19 and 20 were somewhat less efficacious (94-97% inhibition) and phenylpyridine analogue 
57 was markedly inferior (80%). For this class, higher maximal activity seemed to be 
associated with steeper dose-response curves (see Fig. 4 below and additional Figures S1 and 
S2 in the Supplementary data). Nevertheless, this tendency was not observed in the 7-
substituted oxazine/thiazine classes (or the oxazole-based classes), where early lead 17, 
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thiazine dioxide 48 and phenylpyridine 64 each provided 100% inhibition, but two more potent 
analogues, triazole 56 and phenylpyridine 65 (IC90s 0.85 and 0.33 µM, respectively), gave 
slightly lower maximal effects (96-98%). The result with triazole 56 was rather unexpected in 
light of the reverse trend for oxazole analogues rac-12 and 69, and also unfortunate, given its 
better solubility and microsomal stability profile. Overall, based on the data in Table 6, the 
most promising candidates for further assessment as CD leads were the 2-nitroimidazooxazine 
derivatives ent-16, 20, ent-30, 58, 64 and 70. 
 
Fig. 4. Duplicate dose-response curves depicting percentage trypanocidal activity against T. 
cruzi or percentage cytotoxicity toward 3T3 cells for ent-10 (left) and ent-16 (right). 
2.6 Assessment of lead 58 in a chronic infection mouse model of CD 
To conclude this current investigation, we elected to evaluate 58 alongside 1, 2 and 6 in the 
chronic T. cruzi infection mouse model, monitoring the parasite burden using highly sensitive 
bioluminescence imaging [52] (Fig. 5). The choice of 58 (DNDI-8219, a backup lead candidate 
for visceral leishmaniasis [45]) for a second proof-of-concept in vivo efficacy study was based 
on its better solubility (12 µg/mL) and high 24 hour exposure in mice (see Figure S4 in the 
Supplementary data; the mean plasma concentration of 58 at 24 hours was 11 µM), together 
with its strong in vitro activity and suitable safety profile. In this experiment, female BALB/c 
mice (five per group) were infected intraperitoneally with 103 bioluminescent bloodstream 
trypomastigotes of CL Brener T. cruzi strain. Commencing on day 114 p.i., these mice were 
orally dosed with test compounds at 50 or 100 mg/kg once daily for five days. Apart from a 
vehicle-related effect in one case (discussed below), dosing regimens were well tolerated, and 
body weight changes for the mice in this experiment were well within normal thresholds. 
After the end of dosing and a 17 day rest period, treated mice were immunosuppressed using 
cyclophosphamide (200 mg/kg), administered intraperitoneally on days 135, 139 and 143 p.i. 
All untreated mice were found to be bioluminescence positive at each time point. On day 149 
p.i., imaging of mice treated with benznidazole (1) or fexinidazole (6) (100 mg/kg in 5% 
DMSO/HPMC-SV) indicated that all mice were bioluminescence negative, so these were 
designated as cured; similarly, 4 out of 5 mice treated with nifurtimox (2) (100 mg/kg in the 
same vehicle) were cured (see Figure S5 in the Supplementary data for imaging results on 1, 
2, 6 and vehicle). In the case of 58 (dosed at only 50 mg/kg in PEG400), all mice appeared to 
be bioluminescence negative at day 143 p.i., but at day 149, only mouse #5 remained negative 
and was considered cured (Fig. 5A). An ex vivo analysis revealed that the internal organs of 
mouse #4 were also bioluminescence negative, but a small positive signal was detected in the 
mouth/nasal region, while mouse #2 displayed bioluminescent foci in the small intestine and 
caecum (Fig. 5C). However, it should be noted that the vehicle employed for dosing of 58 (200 
µL of PEG400) induced daily diarrhoea in all treated mice, which may have had a detrimental 
effect on the efficacy outcome. This is because PEG400 is known to markedly accelerate liquid 
transit through the small intestine, the primary site of drug absorption in the gastrointestinal 
tract [53]; shorter residence times would result in less drug absorption and suboptimal efficacy.  
14 
 
Fig. 5. In vivo evaluation of 58 (DNDI-8219) as a treatment for chronic stage T. cruzi infection. 
(A) Ventral (V) and dorsal (D) images of each mouse are shown at various days post-infection 
(DPI). (B) Experimental design and inset graph showing average total body bioluminescence 
(sum of ventral and dorsal images) for mice treated with 58 or vehicle only. The pale blue bar 
indicates timing of treatment and the pink bar highlights the cyclophosphamide treatment 
period. The dashed grey line indicates background levels for naïve BALB/c mice. (C) Ex vivo 
assessment of bioluminescence for mice #2, #4 and #5 at day 151 p.i. Heat-maps are on log10 
scales and indicate the intensity of bioluminescence from low (blue) to high (red).  
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The measured thermodynamic solubility of 58 in PEG400 (21 mg/mL) was more than four 
times the concentration employed for this dosing experiment (5 mg/mL), suggesting that 
reduction of the dose volume, alternative formulation, or extension of the treatment period 
beyond 5 days might facilitate an improved therapeutic outcome for this promising lead 
compound in future studies. 
3. Conclusions 
To summarise, in response to a dire need for new medications to treat CD, an early-stage 
chemical library of antitubercular bicyclic nitroimidazole derivatives was screened against T. 
cruzi, and a selection of 12 hits was profiled in vitro. Mouse pharmacokinetic data generated 
on five on these directed our initial focus toward the evaluation of 17 in a CD mouse model, 
albeit, promising efficacy in the acute phase was overturned after immunosuppression with 
cyclophosphamide, implying the need for greater 24 hour plasma levels or better potency. 
Within limited hit expansion studies, highly novel nitrotriazole and nitroimidazothiazine 
dioxide analogues of 17 provided improved microsomal stability, while more active 6R 
enantiomers of several 6S pretomanid derivatives were also earmarked as promising leads for 
follow-up. Further assessment of these and some additional hits derived from our leishmaniasis 
studies in a 48 hour T. cruzi growth inhibition assay pinpointed a set of six 2-
nitroimidazooxazine derivatives that provided superior results (maximal activity of 99-100% 
and IC90 values below 2 µM). Of these, 58 (DNDI-8219) possessed the best drug-like attributes 
(in terms of solubility, metabolic stability and safety) and proved to be effective in completely 
curing one of five mice in a chronic infection mouse model, as well as markedly reducing 
parasite burdens in two other mice. Given the short five-day treatment schedule and less ideal 
formulation administered in that experiment, this result is considered to be very encouraging 
and provides good rationale for future studies of this dual antileishmanial/antitrypanosomal 2-
nitroimidazooxazine class. 
4. Experimental section 
4.1 General information 
Elemental analyses were performed by the Campbell Microanalytical Laboratory, University 
of Otago, Dunedin, New Zealand. Melting points were determined using an Electrothermal 
IA9100 melting point apparatus and are as read. NMR spectra were measured on a Bruker 
Avance 400 spectrometer at 400 MHz for 1H and 100 MHz for 13C and were referenced to Me4Si 
or solvent resonances. Chemical shifts and coupling constants were recorded in units of ppm and 
hertz, respectively. High-resolution electrospray ionisation (HRESIMS) mass spectra were 
determined on a Bruker micrOTOF-Q II mass spectrometer or an Agilent 6530 Q-TOF mass 
spectrometer coupled to an Agilent 1200 series HPLC system. Column chromatography was 
performed on silica gel (Merck 230-400 mesh). Thin-layer chromatography was carried out on 
aluminium-backed silica gel plates (Merck 60 F254), with visualization of components by UV light 
(254 nm), I2, or KMnO4 staining. Tested compounds (including batches screened in vivo) were 
≥95% pure, as determined by elemental analysis and/or by HPLC conducted on an Agilent 
1100 system with diode array detection, using a 150 mm x 3.2 mm Altima 5 µm reversed phase 
C8 or C18 column. Elemental analyses indicated by the symbols of the elements were within ± 
0.4% of the theoretical values. 
4.2 General procedure for the syntheses of aryl bromides 29, ent-32, and 37 (via 35) 
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Sodium hydride (60% in mineral oil, unwashed, 1.4-1.6 equiv) was added to a mixture of (6R)-
2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-ol [39] (28) (1.0 equiv) and the 
appropriate halide (1.5 equiv) in anhydrous DMF (2 mL/100 mg of alcohol) under N2 at 0 °C. 
The mixture was immediately degassed and resealed under N2 and then stirred at 20 °C for 3 
h. The resulting mixture was rapidly cooled (CO2/acetone), quenched with ice/aqueous 
NaHCO3 (5 mL), added to brine (50 mL), and extracted with CH2Cl2 (5 x 50 mL). The 
combined extracts were evaporated to dryness under reduced pressure (at 30 °C) and the 
residue was chromatographed on silica gel (0-0.75% MeOH/CH2Cl2 or 0-2% EtOAc/CH2Cl2) 
and then crystallized to afford the required products. 
4.2.1 (6R)-6-[(4-Bromobenzyl)oxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (29) 
The title compound was obtained from alcohol 28 and 4-bromobenzyl bromide. Cream solid 
(89% yield): mp (MeOH/CH2Cl2/hexane) 190-191 °C; 1H NMR [(CD3)2SO] δ 8.03 (s, 1 H), 
7.54 (br d, J = 8.4 Hz, 2 H), 7.27 (br d, J = 8.4 Hz, 2 H), 4.66 (dt, J = 12.0, 2.2 Hz, 1 H), 4.64 
(d, J = 12.2 Hz, 1 H), 4.60 (d, J = 12.2 Hz, 1 H), 4.46 (br d, J = 12.0 Hz, 1 H), 4.30-4.19 (m, 3 
H). Anal. (C13H12BrN3O4) C, H, N. 
4.2.2 (6R)-6-[(5-Bromopyridin-2-yl)methoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazine (ent-32) 
The title compound was obtained from alcohol 28 and 5-bromo-2-(bromomethyl)pyridine [40] 
(31) (1.2 equiv), using the above procedure for 135 min. Pale yellow solid (95% yield): mp 
(MeOH/CH2Cl2/hexane) 171-173 °C; 1H NMR [(CD3)2SO] δ 8.65 (br d, J = 2.4 Hz, 1 H), 8.05 
(dd, J = 8.4, 2.4 Hz, 1 H), 8.04 (s, 1 H), 7.35 (br d, J = 8.4 Hz, 1 H), 4.76-4.66 (m, 3 H), 4.49 
(br d, J = 11.8 Hz, 1 H), 4.35-4.28 (m, 2 H), 4.24 (dd, J = 13.7, 3.5 Hz, 1 H). Anal. 
(C12H11BrN4O4) C, H, N. 
4.2.3 Synthesis of bromide 37 
4.2.3.1 (6R)-2-Nitro-6-{[3-(triisopropylsilyl)prop-2-yn-1-yl]oxy}-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine (35) 
The title compound was obtained from alcohol 28 and (3-bromoprop-1-yn-1-
yl)triisopropylsilane [41] (34), using the above procedure at 0-5 °C for 110 min. Cream solid 
(87% yield): mp (CH2Cl2/pentane) 89-91 °C; 1H NMR (CDCl3) δ 7.41 (s, 1 H), 4.66-4.60 (m, 
1 H), 4.43-4.33 (m, 4 H), 4.26-4.15 (m, 2 H), 1.08 (s, 21 H); HRESIMS calcd for C18H30N3O4Si 
m/z [M + H]+ 380.2000, found 380.2016. 
4.2.3.2 (6R)-2-Nitro-6-[(prop-2-yn-1-yl)oxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
(36) 
A stirred solution of silyl ether 35 (1.79 g, 4.72 mmol) in anhydrous distilled THF (40 mL) 
under N2 at 0 °C was treated with TBAF (5.05 mL of a 1 M solution in THF, 5.05 mmol). The 
mixture was stirred at 0-6 °C for 2.5 h, then diluted with ice/aqueous NaHCO3 (100 mL) and 
extracted with CH2Cl2 (5 x 100 mL). The combined extracts were evaporated to dryness under 
reduced pressure (at 30 °C) and the residue was chromatographed on silica gel (25-75% 
EtOAc/petroleum ether) to afford the title compound. Pale yellow solid (0.85 g, 81% yield): mp 
(Et2O/pentane) 81-83 °C; 1H NMR (CDCl3) δ 7.42 (s, 1 H), 4.63 (ddd, J = 12.5, 3.8, 2.1 Hz, 1 
H), 4.42-4.33 (m, 3 H), 4.32 (dd, J = 16.6, 2.6 Hz, 1 H), 4.25 (dd, J = 13.0, 3.7 Hz, 1 H), 4.18 
(dt, J = 12.9, 2.4 Hz, 1 H), 2.56 (t, J = 2.4 Hz, 1 H); HRESIMS calcd for C9H9N3NaO4 m/z [M 





A mixture of alkyne 36 (351 mg, 1.57 mmol), 5-bromo-2-iodopyridine (891 mg, 3.14 mmol), 
bis(triphenylphosphine)palladium(II) dichloride (73.7 mg, 0.105 mmol), and copper(I) iodide 
(23.9 mg, 0.125 mmol) in anhydrous DMF (9 mL), anhydrous distilled THF (7 mL) and DIPEA 
(1.80 mL, 10.3 mmol) was degassed for 10 min (vacuum pump) and then N2 was added. The 
mixture was stirred at 20 °C for 24 h and then diluted with ice/aqueous NaHCO3 (100 mL) and 
extracted with CH2Cl2 (5 x 80 mL). The combined extracts were evaporated to dryness under 
reduced pressure (at 30 °C) and the residue was chromatographed on silica gel (0-1% 
MeOH/CH2Cl2) to afford the title compound. Light yellow solid (488 mg, 82% yield): mp 
(MeOH/CH2Cl2/hexane) 190-191 °C; 1H NMR [(CD3)2SO] δ 8.71 (br d, J = 2.4 Hz, 1 H), 8.10 
(dd, J = 8.4, 2.4 Hz, 1 H), 8.04 (s, 1 H), 7.54 (br d, J = 8.4 Hz, 1 H), 4.67 (dt, J = 12.1, 2.5 Hz, 
1 H), 4.62 (s, 2 H), 4.49 (br d, J = 12.0 Hz, 1 H), 4.41-4.36 (m, 1 H), 4.31 (dt, J = 13.7, 2.0 Hz, 
1 H), 4.25 (dd, J = 13.6, 3.2 Hz, 1 H); HRESIMS calcd for C14H12BrN4O4 m/z [M + H]+ 
381.0018, 379.0036, found 381.0037, 379.0055. 
4.3 General procedure for the syntheses of ent-16, ent-30, 33 and ent-33 
A mixture of the bromide (29, 32, or ent-32, 400 mg, 1.0 equiv), arylboronic acid (1.7 equiv) 
and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.07 equiv) in DMF (6 mL) 
and aqueous KHCO3 (2 mL of 2 M, 4.0 mmol) was degassed, and then N2 was added. The 
resulting mixture was stirred at 75 °C for 4 h and then cooled, diluted with brine (100 mL), and 
extracted with CH2Cl2 (3 x 100 mL). The extracts were evaporated to dryness under reduced 
pressure and the residue was chromatographed on silica gel (0-2% MeOH/CH2Cl2) and then 
triturated in CH2Cl2/hexane to afford the required products. 
4.3.1 (6R)-6-{[2'-Chloro-4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy}-2-nitro-6,7-
dihydro-5H-imidazo[2,1-b][1,3]oxazine (ent-16) 
The title compound was obtained from bromide 29 and [2-chloro-4-
(trifluoromethyl)phenyl]boronic acid. Cream solid (81% yield): mp 134-135 °C; 1H NMR 
[(CD3)2SO] δ 8.04 (s, 1 H), 7.98 (br d, J = 1.1 Hz, 1 H), 7.79 (br dd, J = 8.0, 1.2 Hz, 1 H), 7.63 
(d, J = 8.0 Hz, 1 H), 7.46 (br d, J = 8.7 Hz, 2 H), 7.44 (br d, J = 8.7 Hz, 2 H), 4.78-4.68 (m, 3 
H), 4.50 (br d, J = 11.9 Hz, 1 H), 4.35-4.22 (m, 3 H); 13C NMR [(CD3)2SO] δ 147.1, 143.6, 
142.1, 138.1, 136.7, 132.4, 132.3, 129.5 (q, JC-F = 32.9 Hz), 129.1 (2 C), 127.5 (2 C), 126.6 (q, 
JC-F = 3.9 Hz), 124.3 (q, JC-F = 3.7 Hz), 123.3 (q, JC-F = 272.4 Hz), 118.0, 69.3, 67.9, 66.6, 46.8. 
Anal. (C20H15ClF3N3O4) C, H, N. 
4.3.2 (6R)-6-{[2'-Chloro-4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methoxy}-2-nitro-6,7-
dihydro-5H-imidazo[2,1-b][1,3]oxazine (ent-30) 
The title compound was obtained from bromide 29 and [2-chloro-4-
(trifluoromethoxy)phenyl]boronic acid (1.8 equiv), using the above procedure at 70 °C for 16 
h. Cream solid (63% yield): mp 82-85 °C; 1H NMR [(CD3)2SO] δ 8.04 (s, 1 H), 7.68 (br d, J = 
1.8 Hz, 1 H), 7.53 (d, J = 8.5 Hz, 1 H), 7.49-7.43 (m, 1 H), 7.42 (s, 4 H), 4.76-4.67 (m, 3 H), 
4.50 (br d, J = 11.8 Hz, 1 H), 4.35-4.22 (m, 3 H); 13C NMR [(CD3)2SO] δ 147.7, 147.1, 142.1, 
139.0, 137.8, 136.8, 132.8, 132.3, 129.2 (2 C), 127.5 (2 C), 122.6, 120.2, 119.9 (q, JC-F = 257.3 
Hz), 118.0, 69.3, 67.9, 66.6, 46.8. Anal. (C20H15ClF3N3O5) C, H, N. 
4.3.3 (6S)-6-({5-[2-Chloro-4-(trifluoromethyl)phenyl]pyridin-2-yl}methoxy)-2-nitro-6,7-
dihydro-5H-imidazo[2,1-b][1,3]oxazine (33) 
The title compound was obtained from (6S)-6-[(5-bromopyridin-2-yl)methoxy]-2-nitro-6,7-
dihydro-5H-imidazo[2,1-b][1,3]oxazine [40] (32) and [2-chloro-4-
(trifluoromethyl)phenyl]boronic acid (1.8 equiv), using the above procedure at 70 °C for 16 h. 
Pale yellow solid (34% yield): mp 162-164 °C; 1H NMR [(CD3)2SO] δ 8.63 (br d, J = 2.3 Hz, 
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1 H), 8.05 (s, 1 H), 8.04 (br d, J = 1.2 Hz, 1 H), 7.95 (dd, J = 8.0, 2.3 Hz, 1 H), 7.84 (br dd, J 
= 8.1, 1.2 Hz, 1 H), 7.71 (d, J = 7.9 Hz, 1 H), 7.51 (d, J = 8.0 Hz, 1 H), 4.85 (d, J = 13.3 Hz, 1 
H), 4.80 (d, J = 13.3 Hz, 1 H), 4.74 (dt, J = 12.0, 2.6 Hz, 1 H), 4.52 (br d, J = 11.9 Hz, 1 H), 
4.41-4.34 (m, 2 H), 4.28 (dd, J = 13.8, 3.5 Hz, 1 H). Anal. (C19H14ClF3N4O4) C, H, N. 
4.3.4 (6R)-6-({5-[2-Chloro-4-(trifluoromethyl)phenyl]pyridin-2-yl}methoxy)-2-nitro-6,7-
dihydro-5H-imidazo[2,1-b][1,3]oxazine (ent-33) 
The title compound was obtained from bromide ent-32 and [2-chloro-4-
(trifluoromethyl)phenyl]boronic acid (1.8 equiv), using the above procedure at 70 °C for 16 h. 
Pale yellow solid (41% yield): mp 160-161 °C; 1H NMR [(CD3)2SO] δ 8.63 (br d, J = 2.2 Hz, 
1 H), 8.05 (s, 1 H), 8.04 (br d, J = 1.2 Hz, 1 H), 7.95 (dd, J = 8.1, 2.3 Hz, 1 H), 7.84 (br dd, J 
= 8.1, 1.2 Hz, 1 H), 7.71 (d, J = 7.9 Hz, 1 H), 7.51 (d, J = 8.2 Hz, 1 H), 4.85 (d, J = 13.3 Hz, 1 
H), 4.80 (d, J = 13.3 Hz, 1 H), 4.74 (dt, J = 12.0, 2.6 Hz, 1 H), 4.52 (br d, J = 11.9 Hz, 1 H), 
4.41-4.34 (m, 2 H), 4.27 (dd, J = 13.8, 3.5 Hz, 1 H); 13C NMR [(CD3)2SO] δ 157.7, 148.6, 
147.1, 142.1, 140.6, 137.6, 132.7, 132.6, 132.1, 130.2 (q, JC-F = 32.8 Hz), 126.7 (q, JC-F = 3.6 
Hz), 124.5 (q, JC-F = 3.8 Hz), 123.3 (q, JC-F = 273.2 Hz), 120.9, 118.0, 70.6, 68.0, 67.2, 46.7. 
Anal. (C19H14ClF3N4O4) C, H, N. 
4.4 General procedure for the syntheses of ent-19 and ent-20 
A mixture of bromide 37 (300 mg, 1.0 equiv), arylboronic acid (1.8 equiv) and [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.11 equiv) in DMF (6 mL), toluene 
(3.5 mL), and EtOH (2.5 mL) was degassed for 10 min (vacuum pump) and then N2 was added. 
An aqueous solution of sodium carbonate (1.6 mL of 2 M, 3.2 mmol) was added by syringe, 
the stirred mixture was again degassed for 10 min, and then N2 was added. The resulting 
mixture was stirred at 89 °C for 62 min and then cooled, diluted with aqueous NaHCO3 (50 
mL), and extracted with CH2Cl2 (5 x 50 mL). The combined extracts were evaporated to 
dryness under reduced pressure (at 30 °C) and the residue was chromatographed on silica gel 
(0-0.75% MeOH/CH2Cl2) and then crystallized to afford the required products. 
4.4.1 (6R)-2-Nitro-6-[(3-{5-[4-(trifluoromethyl)phenyl]pyridin-2-yl}prop-2-yn-1-yl)oxy]-6,7-
dihydro-5H-imidazo[2,1-b][1,3]oxazine (ent-19) 
The title compound was obtained from bromide 37 and [4-(trifluoromethyl)phenyl]boronic 
acid. Pale yellow-brown solid (60% yield): mp (MeOH/CH2Cl2/hexane) 218-221 °C; 1H NMR 
[(CD3)2SO] δ 8.98 (br d, J = 2.4 Hz, 1 H), 8.21 (dd, J = 8.2, 2.4 Hz, 1 H), 8.06 (s, 1 H), 8.01 
(br d, J = 8.2 Hz, 2 H), 7.87 (br d, J = 8.3 Hz, 2 H), 7.70 (br d, J = 8.2 Hz, 1 H), 4.69 (dt, J = 
12.1, 3.2 Hz, 1 H), 4.66 (s, 2 H), 4.51 (br d, J = 12.1 Hz, 1 H), 4.44-4.39 (m, 1 H), 4.33 (dt, J 
= 13.7, 2.1 Hz, 1 H), 4.27 (dd, J = 13.6, 3.2 Hz, 1 H); 13C NMR [(CD3)2SO] δ 148.4, 147.0, 
142.1, 141.4, 140.3, 135.0, 133.6, 128.8 (q, JC-F = 31.8 Hz), 127.8 (2 C), 127.3, 126.0 (q, JC-F = 
3.7 Hz, 2 C), 124.2 (q, JC-F = 272.1 Hz), 118.0, 86.0, 85.6, 67.8, 66.4, 56.1, 46.6; HRESIMS 
calcd for C21H16F3N4O4 m/z [M + H]+ 445.1118, found 445.1136; HPLC purity: 99.8%. 
4.4.2 (6R)-2-Nitro-6-[(3-{5-[4-(trifluoromethoxy)phenyl]pyridin-2-yl}prop-2-yn-1-yl)oxy]-
6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (ent-20) 
The title compound was obtained from bromide 37 and [4-(trifluoromethoxy)phenyl]boronic 
acid. Light yellow-orange solid (63% yield): mp (MeOH/CH2Cl2/hexane) 205-208 °C; 1H NMR 
[(CD3)2SO] δ 8.93 (br d, J = 2.4 Hz, 1 H), 8.15 (dd, J = 8.2, 2.4 Hz, 1 H), 8.05 (s, 1 H), 7.91 
(br d, J = 8.9 Hz, 2 H), 7.67 (br d, J = 8.2 Hz, 1 H), 7.51 (br d, J = 8.0 Hz, 2 H), 4.69 (dt, J = 
12.1, 2.5 Hz, 1 H), 4.65 (s, 2 H), 4.51 (br d, J = 11.9 Hz, 1 H), 4.43-4.39 (m, 1 H), 4.33 (dt, J 
= 13.7, 1.9 Hz, 1 H), 4.27 (dd, J = 13.6, 3.2 Hz, 1 H); 13C NMR [(CD3)2SO] δ 148.6, 148.2, 
147.0, 142.1, 140.8, 135.5, 134.7, 133.8, 129.0 (2 C), 127.2, 121.7 (2 C), 120.1 (q, JC-F = 256.5 
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Hz), 118.0, 85.7, 67.8, 66.3, 56.1, 54.9, 46.6; HRESIMS calcd for C21H16F3N4O5 m/z [M + H]+ 
461.1067, found 461.1086; HPLC purity: 99.9%. 
4.5 General procedure for the syntheses of intermediate alcohols 39-41 
A mixture of 2-chloro-1-[2-(2-methyloxiran-2-yl)ethyl]-4-nitro-1H-imidazole [31] (38) (250 
mg, 1.0 equiv), powdered potassium carbonate (2.0 equiv) and the appropriately substituted 
phenol (2.0 equiv) in anhydrous 2-butanone (2.5 mL) was stirred in a sealed vial at 82 °C for 
24 h. The resulting cooled mixture was added to water (50 mL), treated with aqueous citric 
acid (2.2 mL of a 1 M solution), and extracted with CH2Cl2 (6 x 50 mL). The combined extracts 
were evaporated to dryness under reduced pressure (at 30 °C) and the residue was 
chromatographed on silica gel (0-2% EtOAc/CH2Cl2) to afford the required products. 
4.5.1 4-(2-Chloro-4-nitro-1H-imidazol-1-yl)-1-[2-chloro-4-(trifluoromethoxy)phenoxy]-2-
methylbutan-2-ol (39) 
The title compound was obtained from epoxide 38 and 2-chloro-4-(trifluoromethoxy)phenol. 
Cream solid (72% yield): mp (pentane triturate) 92-93 °C; 1H NMR (CDCl3) δ 7.82 (s, 1 H), 
7.32 (br d, J = 2.3 Hz, 1 H), 7.13 (br dd, J = 9.0, 2.0 Hz, 1 H), 6.90 (d, J = 9.0 Hz, 1 H), 4.38-
4.22 (m, 2 H), 3.91 (d, J = 8.9 Hz, 1 H), 3.88 (d, J = 8.9 Hz, 1 H), 2.37 (br s, 1 H), 2.29 (ddd, 
J = 13.9, 9.9, 6.1 Hz, 1 H), 2.07 (ddd, J = 13.8, 9.8, 6.2 Hz, 1 H), 1.44 (s, 3 H). Anal. 
(C15H14Cl2F3N3O5) C, H, N. 
4.5.2 4-(2-Chloro-4-nitro-1H-imidazol-1-yl)-1-[3-chloro-4-(trifluoromethoxy)phenoxy]-2-
methylbutan-2-ol (40) 
The title compound was obtained from epoxide 38 and 3-chloro-4-(trifluoromethoxy)phenol, 
using the above procedure for 17 h. Pale yellow oil (68% yield); 1H NMR (CDCl3) δ 7.82 (s, 1 
H), 7.26 (br d, J = 9.0 Hz, 1 H), 7.03 (d, J = 3.0 Hz, 1 H), 6.83 (dd, J = 9.1, 3.0 Hz, 1 H), 4.34-
4.20 (m, 2 H), 3.85 (d, J = 8.9 Hz, 1 H), 3.82 (d, J = 8.9 Hz, 1 H), 2.22 (ddd, J = 13.8, 9.4, 6.5 
Hz, 1 H), 2.18 (br s, 1 H), 2.03 (ddd, J = 13.7, 9.7, 6.5 Hz, 1 H), 1.41 (s, 3 H); HRESIMS calcd 
for C15H15Cl2F3N3O5 m/z [M + H]+ 446.0309, 444.0335, found 446.0306, 444.0337. 
4.5.3 4-(2-Chloro-4-nitro-1H-imidazol-1-yl)-1-[3-fluoro-4-(trifluoromethoxy)phenoxy]-2-
methylbutan-2-ol (41) 
The title compound was obtained from epoxide 38 and 3-fluoro-4-(trifluoromethoxy)phenol 
(2.1 equiv), using the above procedure for 17 h. Pale yellow oil (68% yield); 1H NMR (CDCl3) 
δ 7.82 (s, 1 H), 7.24 (br t, J = 8.8 Hz, 1 H), 6.77 (dd, J = 11.3, 2.9 Hz, 1 H), 6.69 (ddd, J = 9.1, 
2.9, 1.6 Hz, 1 H), 4.34-4.20 (m, 2 H), 3.84 (d, J = 8.9 Hz, 1 H), 3.81 (d, J = 8.9 Hz, 1 H), 2.22 
(ddd, J = 13.8, 9.3, 6.5 Hz, 1 H), 2.19 (br s, 1 H), 2.04 (ddd, J = 13.9, 9.5, 6.7 Hz, 1 H), 1.41 
(s, 3 H); HRESIMS calcd for C15H15ClF4N3O5 m/z [M + H]+ 430.0607, 428.0631, found 
430.0611, 428.0629. 
4.6 General procedure for the syntheses of 42-44 
Sodium hydride (60% in mineral oil, unwashed, 1.5 equiv) was added to a solution of the 
alcohol (39, 40, or 41, 1.0 equiv) in anhydrous DMF (2 mL/100 mg of alcohol) under N2. The 
mixture was immediately degassed and resealed under N2 and then stirred at 20 °C for 160 min. 
The resulting mixture was rapidly cooled (CO2/acetone), quenched with ice/aqueous NaHCO3 
(10 mL), added to brine (40 mL), and extracted with CH2Cl2 (7 x 50 mL). The combined 
extracts were evaporated to dryness under reduced pressure (at 30 °C) and the residue was 





The title compound was obtained from alcohol 39. Cream solid (77% yield): mp 
(CH2Cl2/pentane) 120-121 °C; 1H NMR [(CD3)2SO] δ 8.11 (s, 1 H), 7.58 (br d, J = 2.8 Hz, 1 
H), 7.38 (br dd, J = 9.1, 2.8 Hz, 1 H), 7.30 (d, J = 9.2 Hz, 1 H), 4.34 (d, J = 10.8 Hz, 1 H), 
4.31 (d, J = 10.9 Hz, 1 H), 4.24 (ddd, J = 12.9, 6.9, 6.0 Hz, 1 H), 4.15 (ddd, J = 13.0, 7.1, 5.9 
Hz, 1 H), 2.42 (ddd, J = 14.4, 7.1, 6.0 Hz, 1 H), 2.23 (ddd, J = 14.3, 6.9, 6.0 Hz, 1 H), 1.52 (s, 
3 H); 13C NMR [(CD3)2SO] δ 152.7, 147.3, 142.1, 141.6 (q, JC-F = 1.9 Hz), 123.3. 121.9, 121.4, 
120.0 (q, JC-F = 256.2 Hz), 117.8, 114.6, 80.2, 73.5, 39.7, 27.3, 21.8. Anal. (C15H13ClF3N3O5) 
C, H, N. 
4.6.2 7-{[3-Chloro-4-(trifluoromethoxy)phenoxy]methyl}-7-methyl-2-nitro-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine (43) 
The title compound was obtained from alcohol 40, using the above procedure for 3 h. Cream 
solid (57% yield): mp (CH2Cl2/pentane) 83-85 °C; 1H NMR [(CD3)2SO] δ 8.10 (s, 1 H), 7.50 
(br d, J = 9.1 Hz, 1 H), 7.34 (d, J = 2.9 Hz, 1 H), 7.06 (dd, J = 9.1, 3.0 Hz, 1 H), 4.25 (s, 2 H), 
4.19 (dt, J = 13.1, 6.2 Hz, 1 H), 4.13 (ddd, J = 13.2, 7.8, 5.8 Hz, 1 H), 2.37 (ddd, J = 14.1, 7.7, 
6.3 Hz, 1 H), 2.17 (dt, J = 14.3, 5.9 Hz, 1 H), 1.49 (s, 3 H); 13C NMR [(CD3)2SO] δ 157.4, 
147.2, 142.2, 137.9 (q, JC-F = 1.9 Hz), 127.0, 124.2, 120.1 (q, JC-F = 257.5 Hz), 117.8, 116.5, 
115.3, 80.4, 72.5, 39.5, 26.9, 21.3. Anal. (C15H13ClF3N3O5) C, H, N. 
4.6.3 7-{[3-Fluoro-4-(trifluoromethoxy)phenoxy]methyl}-7-methyl-2-nitro-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine (44) 
The title compound was obtained from alcohol 41, using the above procedure for 2.5 h. Cream 
solid (65% yield): mp (CH2Cl2/pentane) 144-146 °C; 1H NMR [(CD3)2SO] δ 8.10 (s, 1 H), 7.49 
(br t, J = 9.1 Hz, 1 H), 7.21 (dd, J = 12.4, 2.9 Hz, 1 H), 6.91 (ddd, J = 9.2, 2.9, 1.5 Hz, 1 H), 
4.25 (d, J = 10.7 Hz, 1 H), 4.22 (d, J = 10.8 Hz, 1 H), 4.19 (dt, J = 13.1, 6.1 Hz, 1 H), 4.13 
(ddd, J = 13.2, 8.1, 5.7 Hz, 1 H), 2.37 (ddd, J = 14.3, 8.0, 6.3 Hz, 1 H), 2.18 (dt, J = 14.4, 5.8 
Hz, 1 H), 1.49 (s, 3 H); 13C NMR [(CD3)2SO] δ 158.1 (d, JC-F = 9.8 Hz), 154.2 (d, JC-F = 249.3 
Hz), 147.1, 142.2, 128.9 (d, JC-F = 10.8 Hz), 124.8, 120.1 (q, JC-F = 257.2 Hz), 117.8, 111.6 (d, 
JC-F = 3.0 Hz), 104.1 (d, JC-F = 22.1 Hz), 80.3, 72.6, 39.5, 26.9, 21.2. Anal. (C15H13F4N3O5) C, 
H, N. HPLC purity: 96.6%. 
4.7 Syntheses of thiazine derivatives 46-48 
4.7.1 2-Chloro-1-[2-(2-methylthiiran-2-yl)ethyl]-4-nitro-1H-imidazole (45) 
A solution of epoxide 38 (166 mg, 0.717 mmol) in CH2Cl2 (6.5 mL) was treated with thiourea 
on silica gel [42] (1.40 g, containing 0.931 mmol of thiourea). The mixture was stirred at 20 
°C for 6.5 h and then filtered, washing with CH2Cl2. The filtrate was concentrated under 
reduced pressure (at 25 °C) to give an oil, which was chromatographed on silica gel (3:1 
CH2Cl2/petroleum ether then CH2Cl2) to afford the title compound. Pale brown solid (140 mg, 
79% yield): mp (CH2Cl2/pentane) 70-71 °C; 1H NMR (CDCl3) δ 7.76 (s, 1 H), 4.27 (ddd, J = 
14.1, 9.7, 5.8 Hz, 1 H), 4.17 (ddd, J = 14.1, 9.3, 6.0 Hz, 1 H), 2.55 (ddd, J = 13.9, 9.3, 5.8 Hz, 
1 H), 2.45 (d, J = 1.4 Hz, 1 H), 2.38 (d, J = 1.2 Hz, 1 H), 1.89 (ddd, J = 13.9, 9.7, 6.1 Hz, 1 
H), 1.65 (s, 3 H). Anal. (C8H10ClN3O2S) C, H, N. 
4.7.2 7-Methyl-2-nitro-7-{[4-(trifluoromethoxy)phenoxy]methyl}-6,7-dihydro-5H-
imidazo[2,1-b][1,3]thiazine (46) 
A mixture of thiirane 45 (159 mg, 0.642 mmol), powdered potassium carbonate (887 mg, 6.42 
mmol) and 4-(trifluoromethoxy)phenol (0.85 mL, 6.56 mmol) in anhydrous 2-butanone (1.6 
mL) was stirred in a sealed vial at 80 °C for 10.5 h. The resulting cooled mixture was added to 
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water (50 mL) and extracted with CH2Cl2 (6 x 50 mL). The combined extracts were evaporated 
to dryness under reduced pressure (at 30 °C) and the residue was chromatographed twice on 
silica gel (firstly with 0-25% EtOAc/petroleum ether and secondly with CH2Cl2) to afford the 
title compound. Pale yellow solid (68 mg, 27% yield): mp (CH2Cl2/pentane) 130-132 °C; 1H 
NMR [(CD3)2SO] δ 8.46 (s, 1 H), 7.30 (br d, J = 9.0 Hz, 2 H), 7.06 (br d, J = 9.2 Hz, 2 H), 
4.32-4.18 (m, 3 H), 4.17 (d, J = 9.8 Hz, 1 H), 2.43 (ddd, J = 14.6, 6.4, 4.7 Hz, 1 H), 2.25 (ddd, 
J = 14.5, 8.4, 5.2 Hz, 1 H), 1.58 (s, 3 H); 13C NMR [(CD3)2SO] δ 157.0, 146.2, 142.2 (q, JC-F = 
1.6 Hz), 139.0, 123.0, 122.5 (2 C), 120.1 (q, JC-F = 255.3 Hz), 116.1 (2 C), 74.1, 47.3, 42.3, 
31.9, 24.8. Anal. (C15H14F3N3O4S) C, H, N. 
 
4.7.3 7-Methyl-2-nitro-7-{[4-(trifluoromethoxy)phenoxy]methyl}-6,7-dihydro-5H-
imidazo[2,1-b][1,3]thiazine 8-oxide (47) 
A mixture of thiazine 46 (69.4 mg, 0.178 mmol), powdered disodium hydrogen phosphate 
(56.1 mg, 0.395 mmol), and m-CPBA (47.2 mg of 70%, 0.191 mmol) in CH2Cl2 (5 mL) was 
stirred at 20 °C for 17 h. The resulting mixture was added to an ice-cold aqueous solution of 
sodium sulphite (50 mL of 10%) and extracted with CH2Cl2 (4 x 50 mL). The extracts were 
sequentially washed with cold aqueous NaHCO3 (50 mL) and then concentrated under reduced 
pressure, and the remaining oil was chromatographed on silica gel (0-0.5% MeOH/CH2Cl2) to 
afford the title compound as a 1:1 mixture of diastereomers. White solid (69.5 mg, 96% yield): 
mp (Et2O/pentane) 159-161 °C; 1H NMR (CDCl3) δ 7.91, 7.90 (2 s, 1 H), 7.18, 7.13 (2 br d, J 
= 9.0 Hz, 2 H), 6.98, 6.68 (2 br d, J = 9.2 Hz, 2 H), 4.48 (ddd, J = 13.8, 5.8, 2.1 Hz, 0.5 H), 
4.41 (ddd, J = 13.6, 5.5, 4.5 Hz, 0.5 H), 4.37-4.23 (m, 3 x 0.5 H), 4.17 (s, 2 x 0.5 H), 4.01 (d, 
J = 9.4 Hz, 0.5 H), 3.04 (ddd, J = 15.1, 12.8, 5.8 Hz, 0.5 H), 2.92 (ddd, J = 15.6, 10.5, 5.6 Hz, 
0.5 H), 2.36 (dt, J = 15.6, 4.5 Hz, 0.5 H), 2.05 (ddd, J = 15.2, 4.5, 2.1 Hz, 0.5 H), 1.61, 1.44 
(2 s, 3 H). Anal. (C15H14F3N3O5S) C, H, N. 
4.7.4 7-Methyl-2-nitro-7-{[4-(trifluoromethoxy)phenoxy]methyl}-6,7-dihydro-5H-
imidazo[2,1-b][1,3]thiazine 8,8-dioxide (48) 
A mixture of thiazine 46 (20.0 mg, 0.051 mmol), powdered disodium hydrogen phosphate 
(25.6 mg, 0.180 mmol), and m-CPBA (27.5 mg of 70%, 0.112 mmol) in CH2Cl2 (2 mL) was 
stirred at 20 °C for 24 h. Additional m-CPBA (9.5 mg of 70%, 0.039 mmol) was added and the 
mixture was stirred at 20 °C for a further 29 h. The resulting mixture was added to an ice-cold 
aqueous solution of sodium sulphite (50 mL of 2.5%) and extracted with CH2Cl2 (4 x 50 mL). 
The extracts were sequentially washed with cold aqueous NaHCO3 (50 mL) and then 
concentrated under reduced pressure, and the remaining oil was chromatographed on silica gel 
(CH2Cl2) to afford the title compound. White solid (19 mg, 88% yield): mp (CH2Cl2/pentane) 
143-145 °C; 1H NMR [(CD3)2SO] δ 8.69 (s, 1 H), 7.31 (br d, J = 8.5 Hz, 2 H), 6.96 (br d, J = 
9.2 Hz, 2 H), 4.47 (d, J = 10.4 Hz, 1 H), 4.45-4.31 (m, 3 H), 2.71 (dt, J = 15.7, 5.6 Hz, 1 H), 
2.62 (ddd, J = 15.8, 7.2, 5.9 Hz, 1 H), 1.58 (s, 3 H); 13C NMR [(CD3)2SO] δ 156.3, 145.9, 142.4 
(q, JC-F = 1.5 Hz), 141.4, 123.2, 122.6 (2 C), 120.1 (q, JC-F = 255.4 Hz), 116.0 (2 C), 69.4, 61.4, 
43.2, 30.2, 14.8. Anal. (C15H14F3N3O6S) C, H, N. 
4.8 Synthesis of triazole 56 
4.8.1 4-(Benzyloxy)-2-methyl-1-[4-(trifluoromethoxy)phenoxy]butan-2-ol (50) 
The title compound was obtained from 2-[2-(benzyloxy)ethyl]-2-methyloxirane [43] (49), 
potassium carbonate (1.5 equiv) and 4-(trifluoromethoxy)phenol (1.6 equiv), using the general 
procedure described in section 4.5 above for 4.5 days, and following chromatography on silica 
gel (0-3% then 25% Et2O/petroleum ether). Pale yellow oil (81% yield); 1H NMR (CDCl3) δ 
7.37-7.26 (m, 5 H), 7.12 (br d, J = 9.1 Hz, 2 H), 6.85 (br d, J = 9.2 Hz, 2 H), 4.54 (d, J = 11.8 
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Hz, 1 H), 4.50 (d, J = 11.8 Hz, 1 H), 3.81 (d, J = 8.9 Hz, 1 H), 3.78 (d, J = 8.8 Hz, 1 H), 3.78-
3.68 (m, 2 H), 3.54 (s, 1 H), 2.02 (ddd, J = 14.7, 6.2, 4.8 Hz, 1 H), 1.94 (ddd, J = 14.8, 7.1, 5.1 




tert-Butyldimethylsilyl trifluoromethanesulfonate (1.35 mL, 7.71 mmol) was added dropwise 
to a stirred mixture of alcohol 50 (1.59 g, 4.29 mmol) and 2,6-dimethylpyridine (1.05 mL, 9.02 
mmol) in anhydrous CH2Cl2 (24 mL) under N2 at 0 °C. The mixture was stirred at 0 °C for 30 
min and at 20 °C for 65 h, and then added to ice/ aqueous NaHCO3 (50 mL) and extracted with 
CH2Cl2 (5 x 50 mL). The combined extracts were evaporated to dryness under reduced pressure 
(at 30 °C) and the residue was chromatographed on silica gel (0-2% Et2O/petroleum ether) to 
afford the title compound. Colourless oil (1.98 g, 95% yield); 1H NMR (CDCl3) δ 7.35-7.23 
(m, 5 H), 7.12 (br d, J = 9.1 Hz, 2 H), 6.84 (br d, J = 9.2 Hz, 2 H), 4.49 (d, J = 12.0 Hz, 1 H), 
4.46 (d, J = 12.0 Hz, 1 H), 3.76 (d, J = 8.9 Hz, 1 H), 3.74 (d, J = 9.0 Hz, 1 H), 3.72-3.60 (m, 
2 H), 2.00 (dt, J = 14.0, 7.0 Hz, 1 H), 1.90 (ddd, J = 14.0, 7.0, 6.3 Hz, 1 H), 1.35 (s, 3 H), 0.83 
(s, 9 H), 0.09 (s, 3 H), 0.06 (s, 3 H); HRESIMS calcd for C25H35F3NaO4Si m/z [M + Na]+ 
507.2149, found 507.2137. 
4.8.3 3-[(tert-Butyldimethylsilyl)oxy]-3-methyl-4-[4-(trifluoromethoxy)phenoxy]butan-1-ol 
(52) 
A mixture of benzyl ether 51 (1.98 g, 4.09 mmol) and 10% Pd-C (200 mg) in 50% EtOH/EtOAc 
(60 mL) was hydrogenated at 60 psi for 42 h, and then the catalyst was removed by filtration 
through Celite, washing with 33% MeOH/CH2Cl2. The filtrate was concentrated under reduced 
pressure (at 30 °C), and the residual oil was chromatographed on silica gel (0-2% then 20% 
Et2O/petroleum ether) to afford the title compound. Colourless oil (1.61 g, 100% yield); 1H 
NMR (CDCl3) δ 7.15 (br d, J = 9.1 Hz, 2 H), 6.88 (br d, J = 9.2 Hz, 2 H), 3.91-3.79 (m, 3 H), 
3.78 (d, J = 8.8 Hz, 1 H), 2.29 (t, J = 5.3 Hz, 1 H), 1.98 (ddd, J = 14.3, 6.6, 5.6 Hz, 1 H), 1.84 
(ddd, J = 14.3, 6.7, 5.6 Hz, 1 H), 1.41 (s, 3 H), 0.88 (s, 9 H), 0.16 (s, 3 H), 0.12 (s, 3 H); 
HRESIMS calcd for C18H29F3NaO4Si m/z [M + Na]+ 417.1679, found 417.1671. 
4.8.4 tert-Butyl({4-iodo-2-methyl-1-[4-(trifluoromethoxy)phenoxy]butan-2-
yl}oxy)dimethylsilane (53) 
A solution of iodine (1.47 g, 5.79 mmol) in anhydrous CH2Cl2 (7 x 6 mL) was added in portions 
over 40 min (with water bath cooling) to a mixture of alcohol 52 (1.61 g, 4.08 mmol), imidazole 
(724 mg, 10.6 mmol) and triphenylphosphine (1.40 g, 5.34 mmol) in anhydrous CH2Cl2 (24 
mL) under N2. After being stirred at 20 °C for 39 h, the mixture was concentrated under reduced 
pressure (at 25 °C), and then dissolved in CH2Cl2 (5 mL) and added to excess petroleum ether 
(200 mL) at the top of a silica gel column (40 g in petroleum ether), rinsing residues onto the 
column with minimal additional CH2Cl2 (5 x 3 mL). Elution of this mixture and then 5% 
Et2O/petroleum ether gave the title compound. Colourless oil (1.98 g, 96% yield); 1H NMR 
(CDCl3) δ 7.15 (br d, J = 9.1 Hz, 2 H), 6.87 (br d, J = 9.1 Hz, 2 H), 3.74 (d, J = 8.8 Hz, 1 H), 
3.67 (d, J = 8.8 Hz, 1 H), 3.27 (ddd, J = 11.9, 9.1, 5.2 Hz, 1 H), 3.22 (ddd, J = 11.8, 9.1, 5.4 
Hz, 1 H), 2.36 (ddd, J = 13.7, 12.1, 5.4 Hz, 1 H), 2.20 (ddd, J = 13.7, 12.0, 5.2 Hz, 1 H), 1.33 
(s, 3 H), 0.87 (s, 9 H), 0.12 (s, 3 H), 0.09 (s, 3 H); HRESIMS calcd for C18H28F3INaO3Si m/z 





A mixture of iodide 53 (1.98 g, 3.93 mmol), 5-bromo-3-nitro-1H-1,2,4-triazole (54) (872 mg, 
4.52 mmol) and powdered potassium carbonate (629 mg, 4.55 mmol) in anhydrous DMF (8 
mL) under N2 was stirred at 73 °C for 61 h. The cooled mixture was evaporated to dryness 
under reduced pressure (at 25 °C), and the residue was chromatographed on silica gel (20-40% 
CH2Cl2/petroleum ether) to afford the crude adduct 55 (0.995 g, 45% yield) as a red-brown oil. 
This oil was immediately dissolved in anhydrous distilled THF (20 mL), and the resulting 
solution was sealed under N2, cooled to 0 °C, and treated with TBAF (10.5 mL of a 1 M solution 
in THF, 10.5 mmol). The mixture was stirred at 0-20 °C for 24 h, and then added to ice/aqueous 
NaHCO3 (100 mL) and extracted with EtOAc (4 x 100 mL). The combined extracts were 
evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed 
three times on silica gel (firstly with 0-33% EtOAc/petroleum ether, secondly with 75-90% 
CH2Cl2/petroleum ether, and thirdly with 50-60% Et2O/petroleum ether and then Et2O) to 
afford the title compound. Pale yellow gum (185 mg, 28% yield); 1H NMR [(CD3)2SO] δ 7.31 
(br d, J = 9.1 Hz, 2 H), 7.07 (br d, J = 9.2 Hz, 2 H), 4.36 (dt, J = 13.0, 6.1 Hz, 1 H), 4.32 (ddd, 
J = 13.1, 7.4, 5.7 Hz, 1 H), 4.29 (s, 2 H), 2.54 (dt, J = 14.5, 7.3 Hz, 1 H), 2.36 (dt, J = 14.6, 
5.9 Hz, 1 H), 1.56 (s, 3 H); 13C NMR [(CD3)2SO] δ 158.2, 156.8, 155.6, 142.2 (q, JC-F = 2.0 Hz), 
122.6 (2 C), 120.1 (q, JC-F = 255.4 Hz), 116.0 (2 C), 82.9, 72.1, 41.7, 27.1, 21.1. Anal. 
(C14H13F3N4O5) C, H, N. HPLC purity: 100%. 
4.9 Biological and physicochemical assays 
4.9.1 In vitro parasite growth inhibition and cytotoxicity assays 
An initial evaluation of 58 pretomanid analogues (including 23, 25 and ent-25) against T. cruzi 
intracellular amastigotes at the Swiss Tropical institute was conducted according to a standard 
method [10], which employs a Tulahuen C2C4 strain of T. cruzi that expresses the β-
galactosidase gene (LacZ) and L6 rat skeletal myoblast cells as the host cells. The subsequent 
screening of ~900 library compounds against Y strain T. cruzi amastigotes in U2OS cells was 
performed at the Institut Pasteur Korea, South Korea, using a seven-point 3-fold dilution 
image-based assay (with 10 µg/mL being the highest test concentration) to generate % 
inhibition data, as reported [8]. Follow-up IC50/IC90 testing against Tulahuen strain TcVI T. 
cruzi (expressing the β-galactosidase gene) in L6 cells and assessment of cytotoxicity toward 
L6 host cells was carried out at Murdoch University, Australia, according to the published 
protocols [32]. Selected leads were further profiled for potency and maximum activity against 
Tulahuen strain T. cruzi amastigotes in 3T3 fibroblasts (host cells) by employing a 48-hour 
high content image-based assay conducted at Discovery Biology, Griffith Institute for Drug 
Discovery, Griffith University, Australia, as described in a recent article [47]. 
4.9.2 T. cruzi CYP51 inhibition assay 
Selected leads were screened against Tulahuen strain T. cruzi CYP51 (sterol 14α-demethylase) 
in a high throughput fluorescence-based assay run at the Drug Discovery Unit, University of 
Dundee, United Kingdom, according to the published method [46]. 
4.9.3 CYP3A4 inhibition assay 
Five hit compounds (13-17) were assessed for their ability to inhibit CYP3A4/5-mediated 6β-
hydroxylation of testosterone (50 µM) in human liver microsomes at the Centre for Drug 
Candidate Optimisation, Monash University, Australia, using a standard protocol [32]. 
4.9.4 Microsomal stability assays 
Microsomal stability studies on compounds ent-16, ent-19, ent-20, ent-30, 42-44, 48, 56, 65, 
and 70 were performed by WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China, using a 
reported method [30] (except that the concentration of microsomal protein was 0.4 mg/mL). 
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Five hits (13-17) were evaluated for stability toward human liver microsomes at the Centre for 
Drug Candidate Optimisation, Monash University, Australia, via a similar procedure [32]. 
4.9.5 hERG assay 
The effects of compounds rac-11, 16 and 17 on cloned hERG potassium channels expressed in 
Chinese hamster ovary cells were assessed by WuXi AppTec (Shanghai) Co., Ltd., using the 
automated patch clamp method. Six concentrations (0.12, 0.37, 1.11, 3.33, 10, and 30 µM) 
were tested (at room temperature), and at least two replicates were obtained for each. 
4.9.6 Solubility measurements 
The solid compound sample was mixed with water or 0.1 M HCl (enough to make a 2 mM 
solution) in an Eppendorf tube, and the suspension was sonicated for 15 min and then 
centrifuged at 13000 rpm for 6 min. An aliquot of the clear supernatant was diluted 2-fold with 
water (or 0.1 M HCl) and then HPLC was implemented. The kinetic solubility was calculated 
by comparing the peak area obtained with that from a standard solution of the compound in 
DMSO (after allowing for varying dilution factors and injection volumes). 
4.9.7 Ethics statement for animal experiments 
All animal experiments were performed according to institutional ethical guidelines for animal 
care. Mouse model experiments in London were approved by the LSHTM Ethics Committee 
and performed under licence PPL70/8207, according to UK Home Office regulations, Animals 
(Scientific Procedures) Act 1986 and European Directive 2010/63/EU. Pharmacokinetic 
studies in non-infected mice conformed to the Australian Code of Practice for the Care and Use 
of Animals for Scientific Purposes and the protocols were approved by the Monash Institute of 
Pharmaceutical Sciences Animal Ethics Committee. Mouse model experiments in Murdoch 
were similarly carried out with the approval of the Animal Ethics Committee of Murdoch 
University. 
4.9.8 Mouse pharmacokinetics 
The systemic exposures of hit compounds 13-17 were determined at the Centre for Drug 
Candidate Optimisation, Monash University, Australia, as described [32]. Briefly, the 
compounds were administered as single oral doses (50 mg/kg) to groups of 3 male Swiss 
Outbred mice (weighing 25-31 g) using a suspension formulation comprising 7% Tween 80 
and 3% EtOH in deionised water. Two blood samples were collected from each mouse to 
provide duplicate samples (from different mice) at time points of 0.5, 8 and 24 h post-dose. 
Blood was transferred to heparinised tubes containing a stabilisation cocktail to minimise the 
potential for degradation, and centrifuged immediately to collect plasma for analysis by LCMS 
against calibration standards. 
4.9.9 Mouse model for acute T. cruzi infection (Murdoch) 
Compounds 3 and 17 were tested for in vivo efficacy against acute and subchronic phase T. 
cruzi infection at Murdoch University, Australia, according to a reported protocol [32]. Briefly, 
each test group consisted of 5 female Swiss mice, 8 weeks old, approximately 30 g, infected 
intraperitoneally with 50,000 bloodform trypomastigotes of T. cruzi (Tulahuen strain). 
Posaconazole (3, Noxafil diluted with water for injection; 20 mg/kg) and 17 (in HPMC-SV; 
0.5% w/v hydroxypropylmethylcellulose + 0.4% v/v Tween 80 + 0.5% v/v benzyl alcohol in 
deionised H2O with 5% v/v DMSO; 50 mg/kg) were dosed orally, once daily for 20 days, 
commencing on day 8 p.i. Blood parasitemia levels were evaluated over the course of the 20 
days of dosing (on days 8 – prior to dosing, 9, 12, 14, 16, 19, 21, and 28 p.i.) by pricking the 
tail and collecting 3 μL of blood, which was diluted 1:10 with red blood cell lysis and counted 
under the microscope using a neubauer haemocytometer. At the end of the dosing period and 
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following 10 days of rest, animals with very low or undetectable parasitemia were 
immunosuppressed in three cycles, via intraperitoneal administration of cyclophosphamide (50 
mg/kg) once daily for 4 days, followed by 3 days of rest (starting on day 37 p.i.). Animals were 
checked for any recurrence of blood parasitemia periodically during the immunosuppression 
phase (on days 37 – prior to dosing, 44, 51, and 58 p.i.). If parasite rebound was not observed 
after three rounds of immunosuppression, the animals were euthanized and tissues (spleen, 
heart, skeletal muscle and colon) and blood were collected for confirmation of cure by PCR. 
4.9.10 Mouse model for chronic T. cruzi infection (London) 
Compound 58 was tested for in vivo efficacy against chronic T. cruzi infection at the London 
School of Hygiene & Tropical Medicine, United Kingdom, using a published procedure [14]. 
Briefly, each test group consisted of 5 female BALB/c mice, 8 weeks old, approximately 18 g, 
infected intraperitoneally with 103 bloodstream form trypomastigotes of bioluminescent T. 
cruzi (CL Brener genetically transformed with the construct pTRIX2-RE9h). Reference drugs 
1, 2 and 6 (in HPMC-SV; 0.5% w/v hydroxypropylmethylcellulose + 0.4% v/v Tween 80 + 
0.5% v/v benzyl alcohol in deionised H2O with 5% v/v DMSO; 100 mg/kg) and 58 (in PEG400; 
50 mg/kg) were dosed orally, once daily for 5 days, commencing on day 114 p.i., and treated 
mice were monitored regularly by bioluminescence imaging. All treated mice were then 
immunosuppressed via intraperitoneal injection of cyclophosphamide (200 mg/kg) given on 
days 135, 139 and 143 p.i. After final imaging on day 149 p.i., organs were removed and 
assessed for bioluminescence (days 149-151 p.i.). 
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